Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Fresenius    FRE   DE0005785604

FRESENIUS

(FRE)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Fresenius Expects to Miss 2020 Targets on Revised 2019 Outlook

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/07/2018 | 02:32am EST

By Patrick Costello

Fresenius adjusted its mid-term guidance late on Thursday, saying the company no longer expects to meet group targets for 2020 after updating its forecast for next year.

The German health-care company said it expects to see mid-single-digit organic sales growth for 2019, with net income remaining "broadly stable" from 2018.

The company's previously expected group sales to increase at a compounded annual growth rate of 7.1% to 10.3% through 2020, with group net income increasing at a CAGR of 8.3% to 12.6%.

Fresenius said it expects to generate sustainable organic sales growth in the mid-single-digit range from 2020 onward, with group net income expected to grow faster than sales on an organic basis.

Among the group's individual units, Fresenius Medical Care--a provider of dialysis products and services--should generate sales growth and net income in 2019 in line with the levels recorded in 2018, the company said.

It forecasts that the Fresenius Kabi division--an essential drugs and medical device supplier--will deliver mid-single-digit organic sales growth and "low- to mid-single-digit" growth in earnings before interest and taxes next year.

Fresenius Helios, the group's hospital operator unit, expects EBIT to contract at a low- to mid-single digit rate next year, as growth in Spain will be unlikely to offset "headwinds" in Germany resulting from regulatory changes, Fresenius SE said.

The group said it expects to propose a dividend increase for 2018 in line with earnings growth, as well as a further dividend increase in 2019.

The company will release detailed financial guidance for 2019 and on its mid-term targets alongside full-year results for 2018 on Feb. 20.

Write to Patrick Costello at patrick.costello@dowjones.com

Stocks mentioned in the article
ChangeLast1st jan.
FRESENIUS -2.75% 48.74 Delayed Quote.15.01%
FRESENIUS MEDICAL CARE -0.06% 70.46 Delayed Quote.24.40%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on FRESENIUS
02/20EUROPE : Trade talks keep European shares afloat as Sainsbury's, Swedbank sink
RE
02/20FMC expects NxStage deal to close in next couple of days
RE
02/20Fresenius Backs 2019 Outlook, Hopeful About Future
DJ
02/20FRESENIUS MEDICAL CARE : Announces Share-Buyback Program of Up to EUR1 Billion
DJ
01/31FRESENIUS SE & CO. KGAA : Release according to Article 41 of the WpHG [the Germa..
EQ
01/31FRESENIUS SE & CO. KGAA : Release according to Article 40, Section 1 of the WpHG..
EQ
01/29FRESENIUS MEDICAL CARE : FMC extends deadline for NxStage deal until Aug. 6 due ..
RE
01/29FRESENIUS MEDICAL CARE : NxStage Postpone Merger End Date Due to Shutdown
DJ
01/25FRESENIUS SE & CO. KGAA : Release according to Article 40, Section 1 of the WpHG..
EQ
01/24EUROPE : Downbeat Draghi curbs gains on European shares as tech shines
RE
More news
Financials (€)
Sales 2019 34 849 M
EBIT 2019 4 689 M
Net income 2019 1 883 M
Debt 2019 15 122 M
Yield 2019 1,66%
P/E ratio 2019 14,56
P/E ratio 2020 13,66
EV / Sales 2019 1,21x
EV / Sales 2020 1,12x
Capitalization 27 111 M
Chart FRESENIUS
Duration : Period :
Fresenius Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FRESENIUS
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 55,9 €
Spread / Average Target 15%
EPS Revisions
Managers
NameTitle
Stephan Sturm President & Chief Executive Officer
Gerd Krick Chairman-Supervisory Board
Rachel Clare Empey Chief Financial Officer
Niko Stumpfögger Deputy Chairman-Supervisory Board
Klaus-Peter Müller Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
FRESENIUS15.01%0
IHH HEALTHCARE BHD--.--%12 478
BANGKOK DUSIT MEDICAL SERVICES PCL--.--%12 015
AIER EYE HOSPITAL GROUP CO LTD--.--%11 215
RAMSAY HEALTH CARE LIMITED3.72%8 618
PREMIER INC0.80%4 759